Abivax Stock Soars 7.21% Following Promising Clinical Results
The stock showed a significant increase of 7.21% this Monday morning at the opening, bringing the price to 84.80 euros from 79.10 euros the previous day. This rise is part of a particularly strong short-term dynamic, with a cumulative gain of 17.45% over seven days and a spectacular performance of 1,093% over three months. Over one year, the stock has recorded a progression of 921.7%, a growth level that sharply contrasts with the CAC 40’s 4.96% over the same period.
Continued Momentum from Early October
This morning's rebound extends the movement that began in early October, following the presentation of Phase 3 results from the ABTECT trials evaluating obefazimod in the treatment of moderate to severe ulcerative colitis. The data, unveiled on October 5 and 6 during the European Gastroenterology Congress (UEG) in Berlin, revealed a placebo-adjusted clinical remission rate of 16.4% at eight weeks, with high statistical significance. Both trials achieved their primary endpoint with the FDA, with no concerning safety signals across the 1,272 patients included, a significant proportion of whom had previously failed advanced therapies. From October 6, the biotech emerged as the top performer in the SBF 120 with an increase of 8.31%. Following these announcements, several brokers raised their price targets: BTIG raised its target to 120 dollars on October 7, JMP Securities increased it from 95 to 114 dollars, while Morgan Stanley moved it from 71 to 101 dollars. The average analyst consensus, established on October 12, now places the three-month target at 88.02 euros, representing an additional potential of 11.27% compared to Friday's closing price.
Technical Breakthrough This Morning
Technically, the stock this morning has crossed its previous resistance level at 79.10 euros, thereby turning this level into a potential new support. The Relative Strength Index (RSI), which measures the speed and magnitude of price changes, stands at 73, a level above the 70 zone generally considered to indicate an overbought market. This signal suggests a very intense bullish momentum but also a possible technical pause or consolidation in the short term if buyers were to slow down. The MACD, a momentum indicator that follows the difference between two exponential moving averages, shows a line at 2.01 above its signal line at 1.24, with a positive histogram of 0.77. This configuration indicates a confirmed bullish trend in the short term. However, two cash flow indicators slightly temper this reading: the On-Balance Volume (OBV) remains negative at -227,901 and the Chaikin Money Flow (CMF) is at -0.21, indicating that incoming capital flows remain fragile despite the rising prices. This divergence could signal limited volume participation in the rally, an element to monitor in the coming sessions. The price also moves well above its 50-day moving average, set at 68.23 euros, confirming the strength of the underlying trend initiated several weeks ago.
